 |
|
|
| |
Modeling Predicts Clinically Meaningful SVR Rates in Genotype 1 Treatment-Experienced Patients Based on Results in Genotype 1 Treatment-Naïve Patients Treated With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks
|
| |
| |
EASL: Successful Retreatment of HCV Genotype-1 Infected Patients Who Failed Prior Therapy with Peg-interferon + Ribavirin Plus 1 or 2 Other Direct-Acting Antiviral Agents with Sofosbuvir - (04/14/14)
EASL: Successful Retreatment With Sofosbuvir-containing Regimens for HCV Genotype 2 or 3 Infected Patients who Failed Prior Sofosbuvir Plus Ribavirin Therapy - (04/14/14)
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Andrew Muir,1 David R. Nelson,2 Stuart C. Gordon,3 Jordan J. Feld,4 Keyur Patel,1 Eric Lawitz,5 Aasim M. Sheikh,6 Diana M. Brainard,7 William T. Symonds,7 John G. McHutchison,7 B. Nebiyou Bekele,7 Alessandra Mangia,8 Edward J. Gane9
1Duke University Medical Center, Durham, North Carolina, USA; 2University of Florida, Gainesville, Florida, USA; 3Henry Ford Health Systems, Detroit, Michigan, USA; 4University of Toronto, Toronto, Ontario, Canada; 5Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA;
6GI Specialists of Georgia, Marietta, Georgia, USA; 7Gilead Sciences, Inc., Foster City, California, USA; 8Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 9Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
